Western Blot: ERO1L Antibody [NB100-2525] - Analysis of ERO1L in 293 cell lysates.
Immunocytochemistry/ Immunofluorescence: ERO1L Antibody [NB100-2525] - Detection of ERO1L in Hela cells.
Western Blot: ERO1L Antibody [NB100-2525] - Analysis of ERO1L in mouse white adipose tissue using anti-ERO1L antibody. Image from verified customer review.
Western Blot: ERO1L Antibody [NB100-2525] - Thermal injury induces hepatic endoplasmic reticulum (ER) stress response in vivo. Western blots of ER stress proteins and ER calcium handling/chaperone proteins and/or their ...read more
Western Blot: ERO1L Antibody [NB100-2525] - Detection of ERO1 alpha in an endogenous 293T cell lysate.
This ERO1L antibody is useful for Western Blot, where a band ~57 kDa is observed. Depending on the samples used ERO1L can also appear as a doublet which is believed to represent the oxidized and reduced forms of the protein. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
57 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 1 Review rated 4 using NB100-2525 in the following applications:
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
PBS and 1.0% BSA
Immunogen affinity purified
Alternate Names for ERO1L Antibody
Endoplasmic oxidoreductin-1-like protein
ERO1 (S. cerevisiae)-like
ERO1-like (S. cerevisiae)
ERO1-like protein alpha
ERO1L (endoplasmic oxidoreductin-1-like protein) is localized in ER membrane as peripheral membrane protein on lumenal side, its association with ERP44 being essential for its retention in the ER, and is unique in coupleing oxygen reduction to de novo disulfides formation. ERO1L enzyme is broadly distributed at low levels in several tissues with highest levels in upper digestive tract especially the esophagus, and is stimulated by hypoxia via HIF-signaling. ERO1L generally exists as monomer, but has the ability to function as monomer or homodimer and interacts with PDILT. After translation, ERO1L gets n-glycosylated and the disulphide bonds constitute the redox-active center whereby the Cys-94/Cys-99 disulfide bond accept electron from P4HB followed by funneling the same to the active site disulfide Cys-394/Cys-397. ERO1L acts by oxidizing directly P4HB/PDI isomerase through direct disulfide exchange and can associates with ERP44. Its reoxidation probably involves electron transfer to molecular oxygen via FAD and acts independently of GSH. ERO1L is implicated in immunoglobulin folding, oxidative stress, release of unfolded cholera toxin from reduced P4HB/PDI upon Vibrio cholerae infection, and plays a key role in ER stress-induced CHOP-dependent apoptosis through inositol 1,4,5-trisphosphate receptor IP3R1 activation.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.